Profile
Sector:
HealthcareCountry:
United StatesIPO:
13 October 2017Website:
http://www.optinose.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
OPTN Latest News
Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.
OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
OptiNose (OPTN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
OptiNose, Inc. (NASDAQ: OPTN) will be holding its Q1 2024 Results Conference Call on May 15, 2024 at 10:00 AM ET. Company representatives include Jonathan Neely, VP of IR & Business Development, and Dr. Ramy Mahmoud, CEO. Conference call participants include analysts from Lake Street Capital Markets, Piper Sandler, Jefferies, and H.C. Wainwright. The operator begins the call by thanking participants for joining.
Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in patients cared for by ear, nose, and throat (ENT) and allergy specialists, revealed today that its management team will be giving a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
OptiNose (OPTN) reported a quarterly loss of $0.12 per share, slightly higher than the expected loss of $0.10 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.17 per share reported in the same quarter last year.
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
What type of business is OptiNose?
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
What sector is OptiNose in?
OptiNose is in the Healthcare sector
What industry is OptiNose in?
OptiNose is in the Drug Manufacturers - Specialty & Generic industry
What country is OptiNose from?
OptiNose is headquartered in United States
When did OptiNose go public?
OptiNose initial public offering (IPO) was on 13 October 2017
What is OptiNose website?
https://www.optinose.com
Is OptiNose in the S&P 500?
No, OptiNose is not included in the S&P 500 index
Is OptiNose in the NASDAQ 100?
No, OptiNose is not included in the NASDAQ 100 index
Is OptiNose in the Dow Jones?
No, OptiNose is not included in the Dow Jones index
When was OptiNose the previous earnings report?
No data
When does OptiNose earnings report?
The next expected earnings date for OptiNose is 07 March 2025